QuidelOrtho (QDEL) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.8B
Gross Profit
1.3B
46.23%
Operating Income
45.8M
1.65%
Net Income
-2.1B
-73.74%
EPS (Diluted)
-$30.54
Balance Sheet Metrics
Total Assets
6.4B
Total Liabilities
3.4B
Shareholders Equity
3.0B
Debt to Equity
1.15
Cash Flow Metrics
Operating Cash Flow
-1.8B
Free Cash Flow
-112.1M
Revenue & Profitability Trend
QuidelOrtho Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 3.0B | 3.3B | 1.7B | 1.7B |
| Cost of Goods Sold | 1.5B | 1.5B | 1.3B | 420.3M | 312.8M |
| Gross Profit | 1.3B | 1.5B | 1.9B | 1.3B | 1.3B |
| Operating Expenses | 1.0B | 1.0B | 823.8M | 335.3M | 284.8M |
| Operating Income | 45.8M | 252.5M | 979.7M | 915.6M | 1.1B |
| Pre-tax Income | -2.1B | -29.1M | 735.9M | 900.3M | 1.0B |
| Income Tax | -79.5M | -19.0M | 187.2M | 196.1M | 230.0M |
| Net Income | -2.1B | -10.1M | 548.7M | 704.2M | 810.3M |
| EPS (Diluted) | -$30.54 | -$0.15 | $9.56 | $16.43 | $18.60 |
Income Statement Trend
QuidelOrtho Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.2B | 1.3B | 1.6B | 1.4B | 1.1B |
| Non-Current Assets | 5.2B | 7.3B | 7.3B | 990.1M | 728.8M |
| Total Assets | 6.4B | 8.6B | 8.9B | 2.4B | 1.9B |
| Liabilities | |||||
| Current Liabilities | 998.8M | 833.8M | 1.0B | 323.5M | 337.0M |
| Non-Current Liabilities | 2.4B | 2.7B | 2.9B | 177.5M | 201.5M |
| Total Liabilities | 3.4B | 3.6B | 3.9B | 501.0M | 538.5M |
| Equity | |||||
| Total Shareholders Equity | 3.0B | 5.0B | 4.9B | 1.9B | 1.3B |
Balance Sheet Composition
QuidelOrtho Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -2.1B | -10.1M | 548.7M | 704.2M | 810.3M |
| Operating Cash Flow | -1.8B | 430.3M | 845.9M | 913.8M | 479.3M |
| Investing Activities | |||||
| Capital Expenditures | -195.1M | -209.3M | -140.9M | -292.8M | -64.9M |
| Investing Cash Flow | -149.9M | -187.6M | -1.6B | -319.5M | -63.3M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 48.8M | -265.8M | 252.0M | -173.1M | -130.3M |
| Free Cash Flow | -112.1M | 70.9M | 744.4M | 513.1M | 564.8M |
Cash Flow Trend
QuidelOrtho Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.07
Forward P/E
11.63
Price to Book
0.69
Price to Sales
0.75
PEG Ratio
11.63
Profitability Ratios
Profit Margin
-12.97%
Operating Margin
7.03%
Return on Equity
-11.38%
Return on Assets
1.12%
Financial Health
Current Ratio
1.20
Debt to Equity
90.01
Beta
0.09
Per Share Data
EPS (TTM)
-$5.23
Book Value per Share
$44.40
Revenue per Share
$41.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| qdel | 2.1B | -1.07 | 0.69 | -11.38% | -12.97% | 90.01 |
| Abbott Laboratories | 233.3B | 17.42 | 4.78 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 154.3B | 75.79 | 6.91 | 9.50% | 11.58% | 52.16 |
| Masimo | 8.8B | 129.16 | 9.35 | -25.07% | -23.25% | 72.01 |
| Globus Medical | 7.7B | 42.44 | 1.88 | 4.63% | 7.39% | 2.27 |
| Bio-Rad | 7.1B | -3.83 | 1.03 | -27.52% | -85.16% | 20.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.